KeyBanc maintains Overweight rating on West Pharmaceutical stock

West Pharmaceutical (WST) reported robust second-quarter 2025 results, significantly exceeding analyst expectations with an EPS of $1.84 and revenue of $766.5 million. The company achieved 6.8% organic growth, notably driven by a 60% surge in GLP-1 related products, which now constitute 8% of total revenue. Following these strong financials, Evercore ISI raised its price target to $350, while KeyBanc maintained its Overweight rating, anticipating WST will surpass its full-year 2025 organic growth guidance and achieve long-term targets, contributing to the stock's recent 24.95% return.

Analysis

West Pharmaceutical Services (WST) delivered a robust second quarter for 2025, significantly outperforming market expectations. The company reported an EPS of $1.84, a 21.85% surprise over the anticipated $1.51, and revenue of $766.5 million, which was 5.69% ahead of forecasts. This performance was underpinned by strong organic growth of 6.8%, led by an 8.4% increase in the Proprietary Products segment and an 11.3% rise in high-value elastomer components. A key driver of this outperformance is the company's exposure to the rapidly expanding GLP-1 drug market, where related product revenue surged 60% and now constitutes a meaningful 8% of total sales. Despite management maintaining a conservative full-year 2025 organic growth forecast of approximately 3%, sell-side analysts like KeyBanc anticipate an acceleration in the second half of the year, projecting a return to the long-term 7-9% growth target by 2026. This bullish sentiment is echoed by Evercore ISI's price target increase to $350, reflecting the market's confidence in WST's operational resilience and growth trajectory, which has already fueled a 24.95% stock price increase in the past week.

Key Decisions for Investors

• Investors should closely monitor the growth of the GLP-1 related product segment, which surged 60% and now represents 8% of revenue, as it is the primary catalyst for exceeding current growth expectations.
• Consider the disconnect between the company's conservative 3% organic growth guidance for 2025 and analyst projections for a significant beat, as this suggests potential for future upside surprises on earnings calls.
• Given the stock's significant 24.95% return in the past week, investors should weigh the strong fundamental outlook against the risk that the positive news is already largely priced in, potentially warranting a disciplined approach to new or additional positions.